The Indian pharmaceutical industry is a global leader, ranking third in volume and 14th in value, with a market size of over $50 billion. Known as the “pharmacy of the world,” it supplies 20% of global generic medicines and is a key player in vaccines, exporting to over 200 countries. The industry is driven by strong R&D, cost-effective manufacturing, and a skilled workforce.
Companies like Sun Pharma, Dr. Reddy’s, Cipla, and Lupin lead the sector. With increasing healthcare spending, rising chronic diseases, and export demand, India’s pharma industry has immense growth potential, especially in biotechnology, biosimilars, and innovative drug development.
India: The CDMO Capital of the World
India is known as the “CDMO (Contract Development and Manufacturing Organization) capital of the world,” dominating the global pharmaceutical outsourcing market. Indian companies provide end-to-end solutions, including drug development, manufacturing, and packaging, to major global pharma players.
The country’s competitive pricing, skilled workforce, and regulatory expertise make it the preferred hub for outsourced pharmaceutical services. Prominent CDMOs like Lonza, Cipla, and Biocon contribute significantly to India’s position as a leading provider of contract services.
India’s Push for Self-Reliance in API Manufacturing
India’s pharmaceutical industry heavily relies on Active Pharmaceutical Ingredients (APIs), with China being a major supplier. However, India is now prioritizing self-reliance in API production to reduce this dependency.
By boosting domestic manufacturing capabilities and creating more robust supply chains, India aims to safeguard its pharmaceutical sector and reduce vulnerability to geopolitical risks. This push for self-reliance is critical in ensuring a consistent supply of high-quality medicines both domestically and globally.
Share Price
The shares of Bajaj Healthcare hit an Upper circuit of 20% at Rs. 563.1 as of December 18, 2024. The stock has also given a return of more than 40% in December 2024
Recent Updates
Bajaj Healthcare’s New CDMO Contract
Bajaj Healthcare Limited entered into a definitive CDMO contract with UK/EU-based companies for 15 new APIs last week. This addition complements the earlier agreement made in February 2024, expanding the company’s footprint in the global pharmaceutical market. The new pipeline includes both off-patent generic APIs and patented molecules, reinforcing the company’s diverse portfolio.
Strengthening Manufacturing and R&D Capabilities
Mr. Anil Jain, Managing Director of Bajaj Healthcare, highlighted the company’s commitment to cost-effective synthesis routes and manufacturing expansion. With facilities approved by USFDA, EU, and now TGA Australia, the company is poised for greater growth in global markets, particularly in Australia, New Zealand, and South Africa.
Importance of a Strong API Order Book
A robust order book for APIs is crucial for sustaining long-term growth and profitability. The expansion of Bajaj Healthcare’s order pipeline reflects its growing influence in the global pharmaceutical industry, ensuring continued demand for high-quality, cost-effective APIs.
About the Company
Incorporated in 1993, Bajaj Healthcare Ltd (BHL) is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and Formulations. The company specializes in the development, supply, and manufacturing of Amino Acids, Nutritional Supplements, and APIs for the pharmaceutical, nutraceutical, and food industries.
BHL produces a wide range of formulations, including tablets, capsules, and powders, catering to over 550 clients globally. With exports to more than 62 countries across Europe, the USA, Africa, Australia, and other regions, Bajaj Healthcare has established a strong international presence, known for its high-quality products and commitment to innovation in the healthcare sector.
Written By: Dipangshu Kundu
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
